Shailender Bhatia MDDepartment of Medicine, University of Washington, Seattle, Washington
Dr. Shailender Bhatia is an Associate Professor in the Medical Oncology division at the University of Washington (UW)/Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA. He also serves as the Clinical and Research Director of the Melanoma-Renal program at the UW/FHCRC. He received his MBBS (equivalent to MD) degree at the prestigious All India Institute of Medical Sciences (AIIMS) in New Delhi, INDIA and completed his Internal Medicine Internship and Residency at the University of Connecticut Health Center, Farmington, CT. He completed his fellowship in Hematology/Oncology at the UW/FHCRC, Seattle, WA.
Dr. Bhatia’s research efforts are mostly focused on improving outcomes in skin cancers (especially Melanoma and Merkel cell carcinoma). He has led numerous clinical trials of all phases investigating novel immunotherapy approaches in skin cancers. He has a special interest in intra-tumoral and targeted immunotherapy trials that deliver the drugs into the tumor microenvironment to spare systemic toxicity.
DisclosuresDr. Bhatia reports the following:
- Advisory board/Consultant (with honorarium): Genentech, Bristol-Myers Squibb, EMD-Serono, Sanofi-Genzyme, Castle Biosciences, Exicure.
- Speaker Bureau: None
- Research grants (to institution): Bristol-Myers Squibb, EMD-Serono, Merck, Novartis, Immune Design, Incyte, Oncosec, Nantkwest, Exicure, Nektar, Amphivena, Checkmate, Xencor, 4SC.
- Stock/Equity: Moderna